HC Wainwright started coverage on shares of NervGen Pharma (NASDAQ:NGEN – Free Report) in a research report released on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $18.00 price target on the stock.
NervGen Pharma Price Performance
Shares of NASDAQ NGEN opened at $3.85 on Monday. NervGen Pharma has a twelve month low of $1.50 and a twelve month high of $6.30.
About NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.
The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.
Recommended Stories
Receive News & Ratings for NervGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NervGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
